CompareLets see the graphs GAP!
The company also confirms that it is to meet in December with staff at the U.S. National Cancer Institute (NCI) in Bethesda, Md., in order to review the data and comparative results generated by the NCI in its recent single-dose and five-dose testing of GAP-107B8. The NCI is an institute of the National Institutes of Health, the primary U.S. federal agency for conducting and supporting medical research. The NCI has a mandate to work with and assist industry and academia to develop novel drug compounds that could potentially make a material difference in the war against cancer. Management anticipates that discussions with NCI will be continuing as the company's development of GAP-107B8 continues, and significant outcomes of these discussions, and additional data from this testing program, will be announced as they become known and are fully analyzed by the company.